The Hippo effector YAP promotes resistance to RAF- and MEK-targeted cancer therapies  

Oleh:

Luping, Lin ; Sabnis, Amit J ; Chan, Elton ; Olivas, Victor ; Cade, Lindsay

Jenis: Article from Journal - ilmiah internasional
Dalam koleksi: Nature Genetics vol. 47 no. 03 (Mar. 2015), halaman 250–256.

Ketersediaan

Perpustakaan FK Nomor Panggil: N12.K Non-tandon: 1 (dapat dipinjam: 0) Tandon: tidak ada

Lihat Detail Induk

Isi artikel

Resistance to RAF- and MEK-targeted therapy is a major clinical challenge1, 2, 3, 4. RAF and MEK inhibitors are initially but only transiently effective in some but not all patients with BRAF gene mutation and are largely ineffective in those with RAS gene mutation because of resistance5, 6, 7, 8, 9, 10, 11, 12, 13, 14. Through a genetic screen in BRAF-mutant tumor cells, we show that the Hippo pathway effector YAP (encoded by YAP1) acts as a parallel survival input to promote resistance to RAF and MEK inhibitor therapy. Combined YAP and RAF or MEK inhibition was synthetically lethal not only in several BRAF-mutant tumor types but also in RAS-mutant tumors. Increased YAP in tumors harboring BRAF V600E was a biomarker of worse initial response to RAF and MEK inhibition in patients, establishing the clinical relevance of our findings. Our data identify YAP as a new mechanism of resistance to RAF- and MEK-targeted therapy. The findings unveil the synthetic lethality of combined suppression of YAP and RAF or MEK as a promising strategy to enhance treatment response and patient survival.

Opini Anda

Klik untuk menuliskan opini Anda tentang koleksi ini!

Kembali